(-0.58%) 5 042.41 points
(-0.97%) 38 088 points
(-0.85%) 15 580 points
(0.16%) $82.94
(-1.63%) $1.626
(0.13%) $2 341.50
(0.12%) $27.38
(0.82%) $923.35
(-0.33%) $0.931
(-0.17%) $10.96
(-0.47%) $0.799
(-0.05%) $92.27
Live Chart Being Loaded With Signals
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally...
Stats | |
---|---|
Today's Volume | 184 404 |
Average Volume | 308 601 |
Market Cap | 126.14M |
EPS | £0 ( 2024-03-25 ) |
Last Dividend | £1.200 ( 2022-11-02 ) |
Next Dividend | £0 ( N/A ) |
P/E | 27.80 |
ATR14 | £0.468 (1.65%) |
EKF Diagnostics Holdings Correlation
10 Most Positive Correlations | |
---|---|
MPL.L | 0.932 |
PDL.L | 0.924 |
TPX.L | 0.923 |
OMIP.L | 0.916 |
RDT.L | 0.913 |
SCLP.L | 0.913 |
3SNV.L | 0.909 |
TBLD.L | 0.909 |
3SUB.L | 0.906 |
DSW.L | 0.902 |
10 Most Negative Correlations | |
---|---|
AEXG.L | -0.959 |
EMR.L | -0.958 |
CFX.L | -0.957 |
INSE.L | -0.949 |
SPEC.L | -0.939 |
VAST.L | -0.939 |
SKL.L | -0.938 |
NWT.L | -0.934 |
IPF.L | -0.932 |
GRA.L | -0.926 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
EKF Diagnostics Holdings Financials
Annual | 2023 |
Revenue: | £52.61M |
Gross Profit: | £24.44M (46.45 %) |
EPS: | £0.00520 |
Q4 | 2023 |
Revenue: | £25.74M |
Gross Profit: | £12.42M (48.25 %) |
EPS: | £0.00600 |
Q2 | 2023 |
Revenue: | £26.87M |
Gross Profit: | £12.02M (44.72 %) |
EPS: | £-0.000800 |
Q4 | 2022 |
Revenue: | £29.16M |
Gross Profit: | £13.07M (44.81 %) |
EPS: | £-0.0271 |
Financial Reports:
No articles found.
EKF Diagnostics Holdings Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£1.200 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £1.000 | 2020-11-04 |
Last Dividend | £1.200 | 2022-11-02 |
Next Dividend | £0 | N/A |
Payout Date | 2022-12-01 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | £3.30 | -- |
Avg. Dividend % Per Year | 0.73% | -- |
Score | 3.07 | -- |
Div. Sustainability Score | 9.61 | |
Div.Growth Potential Score | 5.30 | |
Div. Directional Score | 7.46 | -- |
Year | Amount | Yield |
---|---|---|
2020 | £1.000 | 2.98% |
2021 | £1.100 | 1.62% |
2022 | £1.200 | 1.58% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SDG.L | Dividend Knight | 2023-07-13 | Annually | 32 | 1.16% | |
ICGT.L | Dividend Knight | 2023-08-17 | Quarterly | 43 | 1.50% | |
BME.L | Dividend King | 2023-06-29 | Semi-Annually | 11 | 4.74% | |
WKOF.L | Dividend Junior | 2023-05-09 | Annually | 11 | 1.78% | |
NICL.L | Dividend King | 2023-08-03 | Semi-Annually | 32 | 1.45% | |
ENOG.L | Dividend King | 2023-09-14 | Quarterly | 3 | 3.46% | |
SOLI.L | Dividend Knight | 2023-09-07 | Semi-Annually | 29 | 1.07% | |
JDG.L | Dividend Knight | 2023-10-05 | Semi-Annually | 19 | 0.54% | |
BYG.L | Dividend Knight | 2023-07-06 | Semi-Annually | 22 | 1.91% | |
PHLL.L | Dividend Knight | 2023-09-28 | Semi-Annually | 3 | 2.65% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0447 | 1.500 | 9.11 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0291 | 1.200 | 9.03 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0358 | 1.500 | -0.713 | -1.070 | [0.1 - 1] |
payoutRatioTTM | 2.32 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 2.69 | 0.800 | 1.545 | 1.236 | [1 - 3] |
quickRatioTTM | 1.768 | 0.800 | 4.31 | 3.45 | [0.8 - 2.5] |
cashRatioTTM | 0.814 | 1.500 | 6.59 | 9.89 | [0.2 - 2] |
debtRatioTTM | 0.0431 | -1.500 | 9.28 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 63.41 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0139 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.00146 | 2.00 | -0.000730 | -0.00146 | [0 - 20] |
debtEquityRatioTTM | 0.0519 | -1.500 | 9.79 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.464 | 1.000 | 5.59 | 5.59 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0904 | 1.000 | -0.192 | -0.192 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.813 | 1.000 | 1.039 | 1.039 | [0.2 - 2] |
assetTurnoverTTM | 0.651 | 0.800 | 9.00 | 7.20 | [0.5 - 2] |
Total Score | 9.61 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 53.62 | 1.000 | 4.68 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0358 | 2.50 | -0.458 | -1.070 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.00146 | 2.00 | -0.000487 | -0.00146 | [0 - 30] |
dividendYielPercentageTTM | 4.32 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0139 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 2.32 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 53.62 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.120 | 1.000 | 9.50 | 0 | [0.1 - 0.5] |
Total Score | 5.30 |
EKF Diagnostics Holdings
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators